HomeCompareENTO vs VICI

ENTO vs VICI: Dividend Comparison 2026

ENTO yields 70.18% · VICI yields 6.52%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ENTO wins by $93.7K in total portfolio value
10 years
ENTO
ENTO
● Live price
70.18%
Share price
$2.85
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.06M
Annual income
$278,697.01
Full ENTO calculator →
VICI
VICI Properties Inc.
● Live price
6.52%
Share price
$27.32
Annual div
$1.78
5Y div CAGR
44.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$966.2K
Annual income
$607,376.13
Full VICI calculator →

Portfolio growth — ENTO vs VICI

📍 ENTO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodENTOVICI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ENTO + VICI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ENTO pays
VICI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ENTO
Annual income on $10K today (after 15% tax)
$5,964.91/yr
After 10yr DRIP, annual income (after tax)
$236,892.46/yr
VICI
Annual income on $10K today (after 15% tax)
$554.58/yr
After 10yr DRIP, annual income (after tax)
$516,269.71/yr
At 15% tax rate, VICI beats the other by $279,377.25/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ENTO + VICI for your $10,000?

ENTO: 50%VICI: 50%
100% VICI50/50100% ENTO
Portfolio after 10yr
$1.01M
Annual income
$443,036.57/yr
Blended yield
43.73%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VICI right now

ENTO
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-1.6
Piotroski
2/9
VICI
Analyst Ratings
20
Buy
6
Hold
Consensus: Buy
Price Target
$31.60
+15.7% upside vs current
Range: $30.00 — $33.00
Altman Z
1.4
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ENTO buys
0
VICI buys
0
No recent congressional trades found for ENTO or VICI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricENTOVICI
Forward yield70.18%6.52%
Annual dividend / share$2.00$1.78
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%44.3%
Portfolio after 10y$1.06M$966.2K
Annual income after 10y$278,697.01$607,376.13
Total dividends collected$903.3K$926.2K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: ENTO vs VICI ($10,000, DRIP)

YearENTO PortfolioENTO Income/yrVICI PortfolioVICI Income/yrGap
1← crossover$17,718$7,017.54$11,361$941.49+$6.4KENTO
2$30,578$11,619.97$13,320$1,481.32+$17.3KENTO
3$51,460$18,742.30$16,284$2,405.01+$35.2KENTO
4$84,541$29,478.65$21,040$4,071.78+$63.5KENTO
5$135,720$45,260.50$29,209$7,285.49+$106.5KENTO
6$213,126$67,906.19$44,443$14,006.51+$168.7KENTO
7$327,705$99,659.70$75,822$29,512.55+$251.9KENTO
8$493,857$143,212.72$148,733$69,726.75+$345.1KENTO
9$730,132$201,704.73$344,394$189,413.75+$385.7KENTO
10$1,059,938$278,697.01$966,234$607,376.13+$93.7KENTO

ENTO vs VICI: Complete Analysis 2026

ENTOStock

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; capeserod, a selective 5-HT4 receptor partial agonist to treat gastroparesis; and niclosamide, an oral small molecule with anti-inflammatory properties for patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. It is also developing CypCel, a disease management tool for monitoring the intestinal health of recovering celiac disease patients. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

Full ENTO Calculator →

VICIREIT

VICI Properties is an experiential real estate investment trust that owns one of the largest portfolios of market-leading gaming, hospitality and entertainment destinations, including the world-renowned Caesars Palace. VICI Properties' national, geographically diverse portfolio consists of 29 gaming facilities comprising over 48 million square feet and features approximately 19,200 hotel rooms and more than 200 restaurants, bars and nightclubs. Its properties are leased to industry leading gaming and hospitality operators, including Caesars Entertainment, Inc., Century Casinos Inc., Hard Rock International, JACK Entertainment and Penn National Gaming, Inc. VICI Properties also owns four championship golf courses and 34 acres of undeveloped land adjacent to the Las Vegas Strip. VICI Properties' strategy is to create the nation's highest quality and most productive experiential real estate portfolio.

Full VICI Calculator →
📬

Get this ENTO vs VICI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ENTO vs SCHDENTO vs JEPIENTO vs OENTO vs KOENTO vs MAINENTO vs NNNENTO vs EPRTENTO vs ADC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.